Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
+0.02 (+3.85%)
as of 12:14 EST

Last 0.54
Change +0.02 (+3.85%)
Open 0.53
Prev. Close 0.52
Today's Range
0.52
0.57
52wk Range
0.51
3.72
Volume 173,213
Avg Volume 510,615
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
BIOC +3.85% -38.44% -66.77%
DJIA -0.33% +3.79% +11.78%
S&P 500 -0.06% +4.76% +16.01%

Key Statistics

Annual EPS -2.67
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 15,030
Weighted Alpha -77.45
Standard Deviation +0.69
Profit Margin 3.63%
Beta 1.88

Growth Rates

YTD -37.79%
1-Year -66.45%
3-Year -97.96%
5-Year -99.83%

Opinion

Sell Hold Buy

Recent Headlines

Biocept Reports Third Quarter 2019 Financial Results

PR Newswire via COMTEX - Wed Nov 13, 04:05PM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 0.54 (+0.02)

Biocept Announces CE IVD Marks and Availability of its

PR Newswire via COMTEX - Thu Nov 07, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conf(full story)
BIOC: 0.54 (+0.02)

Biocept to Release Third Quarter 2019 Financial

PR Newswire via COMTEX - Wed Nov 06, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it (full story)
BIOC: 0.54 (+0.02)

Biocept's Target Selector(TM) Tests and Kits to Be

PR Newswire via COMTEX - Mon Nov 04, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.54 (+0.02)

Biocept's Target Selector(TM) ctDNA Platform

PR Newswire via COMTEX - Mon Oct 07, 08:05AM EDT
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publ(full story)
BIOC: 0.54 (+0.02)